H.C. Wainwright Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3
Buy Rating Justified by Opko Health's Promising OXM Candidate and Strategic Asset Sale
Barrington Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $2.25
Piper Sandler Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3
Opko Health (OPK) Receives a Buy From Piper Sandler
H.C. Wainwright Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3
Opko Health's Strategic Moves and Pipeline Progress Prompt Buy Rating
OPKO Health Analyst Ratings
Buy Rating Affirmed for OPKO Health Amid Strategic Partnerships and Promising Pipeline Developments
Opko Health Holds Strong Buy Rating: Financial Resilience and Strategic Growth Fuel Optimism
Piper Sandler Adjusts Price Target on OPKO Health to $3 From $5, Maintains Overweight Rating
OPKO Health Analyst Ratings
Opko Health (OPK) Gets a Buy From Piper Sandler
Analysts' Top Healthcare Picks: Opko Health (OPK), Pharming Group (PHAR)
OPKO Health Analyst Ratings
HC Wainwright & Co. Reiterates Buy on OPKO Health, Maintains $3 Price Target
Piper Sandler Sticks to Its Buy Rating for Opko Health (OPK)
Opko Health Poised for Growth: Buy Rating Affirmed Amid Topline Expansion and Strategic Transactions
Opko Health Buy Rating Backed by Strategic Asset Sale and Promising Oral Drug Candidate
OPKO Health Analyst Ratings